Biofrontera AG
BFAGY
Other OTC2.48
USD
+0.05
- -
Biofrontera AG
BFAGY
(Other OTC)
Recent
price
2.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biofrontera AG Biofrontera AG is a biopharmaceutical company specializing in the development, manufacturing and commercialization of dermatological drugs and medical cosmetics for the care, protection and treatment of skin conditions. The company offers Ameluz®, a topical prescription nanoemulsion gel containing aminolevulinic acid hydrochloride approved for photodynamic therapy (PDT) of actinic keratosis and certain superficial skin cancers and precursors; BF-RhodoLED® and RhodoLED® XL, proprietary red-light LED lamps emitting at 635 nm wavelength optimized for PDT illumination with adjustable intensity and fan for patient comfort; and Belixos®, a dermocosmetics line including belixos® ACTIVE CARE foam incorporating mahonia extract for soothing irritated, itchy skin associated with atopic dermatitis, psoriasis and daily irritations. Biofrontera AG operates primarily in the dermatology segment targeting healthcare providers such as dermatologists and clinics, with sales in Europe including Germany, Spain and the UK; previously significant U.S. revenue streams; and minor other regions. Founded in 1997 and headquartered in Leverkusen, Germany, the company lists on the Frankfurt Stock Exchange Prime Standard under ticker B8F and maintains 87 employees focused on pharmaceuticals. In a major 2025 restructuring announced June 30, Biofrontera AG transferred all U.S. rights, New Drug Application, patents, manufacturing responsibilities and commercial assets for Ameluz® and RhodoLED® products to its former U.S. subsidiary Biofrontera Inc. (NASDAQ: BFRI) in exchange for a 10% equity stake, a royalty-based agreement replacing prior transfer pricing, and settlement of obligations, enabling cost reductions, improved gross margins starting late 2025 and full U.S. operational independence for the subsidiary while aligning long-term interests.